Guggenheim analyst Vamil Divan initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $9 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.